ClinicalTrials.gg
Status unknownNCT00335088Updated Jun 1, 2007

Local Moxifloxacin and Povidone Iodine Versus Povidone Iodine Alone as a Prophylaxis Before Eye Operations

A Phase 3 interventional study of Moxifloxacin and Povidone Iodine vs Povidone Iodine in Eye Infections, sponsored by HaEmek Medical Center, Israel. Status unknown at 1 site in Israel. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2007-06-01.

Sponsored by HaEmek Medical Center, Israel · Phase 3, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Mar 2007), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 3
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Study summary

The hypothesis is that povidone iodine alone is sufficient for sterilization of the lacrimal sac and eye lids before intraocular surgeries. Patients admitted for various intraocular surgeries will be randomly allocated to prophylactic local therapy with either moxifloxacin and povidone iodine or povidone iodine alone before surgery. Lacrimal sac and eye lid cultures will be obtained before the local therapy and just before surgery.

Read the detailed description

Over all 500 patients admitted for various intraocular surgeries will be included in the study. The study will be prospective, double blind, placebo controlled, and randomized. Patients will be randomly allocated to prophylactic local therapy with either moxifloxacin and povidone iodine or povidone iodine alone before surgery. For patients treated with povidone iodine alone a placebo will also be given. Lacrimal sac and eye lid cultures will be obtained before the local therapy and just before surgery. All patients will be followed for 6 weeks for symptoms and signs of infection. Bacterial and fungal culture results will be compared between the 2 groups.

02

Conditions studied

  • Eye Infections

Browse trials for

Keywords

  • Prophylaxis,
  • Intraocular surgery
  • Lacrimal sac
  • Eye lid
  • No conditions
03

In context

Eye Infections

35 studies on the registry are indexed under Eye Infections; 4 are open to participants now.

This study's planned enrollment of 500 is above the median of 120 across 22 interventional studies indexed under Eye Infections.

Browse Eye Infections studies →

Lead sponsor

HaEmek Medical Center, Israel is the lead sponsor of 237 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > 20 years.
  • Various intraocular surgeries

Exclusion criteria

Exclusion Criteria:

  • Need for emergency therapy, immunosuppression, any malignancy, psychomotor retardation, drug and alcohol abuse.
05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
500 participants (estimated)

Interventions

  • DrugMoxifloxacin and Povidone Iodine vs Povidone Iodine
06

What researchers measure

Primary outcomes

  1. Type and amount of bacterial growth

  2. Post surgery infections

07

Study locations

1 of 1 sites recruiting
  • Ophthalmology Department, HaEmek Medical Center, Afula, Israel
    Afula, 18101, Israel
    • Orly Halachmi, MD · Contact · 972-4-6494344
    • Dan Miron, MD · Contact · miron_da@yahoo.com · 972-4-6494316
    • Yoram Kenes, PhD · Sub investigator
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 1, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00335088
First posted
Jun 8, 2006
Start date
Jun 2006
Completion
May 2007 (estimated)
Last update
Jun 1, 2007

Study contacts

Orly Halachmi, MD
Contact
972-4-649344
Dan Miron, MD
Contact
miron_da@yahoo.om
972-4-6404316
Dan Miron, MD
study director · HaEmek Medicak Center, Afula, Israel
Orky Halachmi, MD
principal investigator · HaEmek Medical Center, Afula, Israel

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion